Abstract:Background: HER2-positive breast cancer is usually associated to the more aggressive progression and the worse prognosis, but the mechanism underlying the innate resistance to HER2-targeted therapy remains elusive. The scaffold protein SH3-domain-binding glutamic acid-rich protein-like protein (SH3BGRL) is indicated as a tumor suppressor in some cancers, but it is highly expressed in breast cancers. Here we characterized the tumorigenic function of SH3BGRL in HER2-expressing breast cancer cells and the subsequent effect in HER2-targeted therapies. Methods: The interaction of SH3BGRL to HER2 were characterized with various truncated SH3BGRL mutants by immunoprecipitation and molecule docking simulation. The physiological roles of SH3BGRL interacting with HER2 in tumor progression and therapy implication were characterized by gain and loss of function approaches in vitro and in vivo. Immunohistochemistry was used for detections of SH3BGRL and p-HER2 (Y1196) expressions in xenografted tumors and human breast cancer tissues. Clinical relevance of SH3BGRL expression with HER2 was validated with both breast patient sample and the public data analyses. Results: Our results demonstrated that SH3BGRL directly binds with HER2 on cell membrane via its motifs α1, α2 helixes and β3 sheet, which postpones HER2 internalization upon EGF stimulation. Consequently, the association between SH3BGRL and HER2 contributed to the prolonged HER2 phosphorylation at specific tyrosine sites, especially at Y1196, and their downstream signaling activation. The relevance between SH3BGRL expression and p-HER2 (Y1196) phosphorylation was validated in both xenografted tumors and the breast cancer patient tissues. Mechanistically, SH3BGRL promoted breast tumor cell proliferation and survival, while reduced the cell sensitivity to anti-tumor drugs, especially to the HER2-targeted drugs. In contrast, Silencing SH3BGRL or inhibiting its downstream signals efficiently induced apoptosis of breast tumor cells with HER2 and SH3BGRL doubly positive expression. Database analysis also highlighted that SH3BGRL is a poor prognostic marker, especially for HER2-positive breast cancers. Conclusions: Our results disclose SH3BGRL as a novel posttranslational modulator of HER2 hyperactivation, which can lead to the intrinsic resistance to HER2-targeted therapy. SH3BGRL would be a pivotal therapy target and a diagnostic marker to HER2-positve patients. Thus, targeting SH3BGRL or the downstream signaling could relieve the innate resistance to some HER2-tageted therapies for both HER2 and SH3BGRL-postive breast cancers.

EZH2-mediated Epigenetic Suppression of SH3BGRL Potently Inhibits Lung Cancer Progression

SH3GL3 Functions As a Potent Tumor Suppressor in Lung Cancer in a SH3 Domain Dependent Manner.

SH3BGRL Suppresses Liver Tumor Progression through Enhanced ATG5-Dependent Autophagy

EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells

The Polycomb Group Protein Ezh2 Inhibits Lung Cancer Cell Growth by Repressing the Transcription Factor Nrf2

SHC1 Promotes Lung Cancer Metastasis by Interacting with EGFR

Schisandrin B inhibits epithelial‑mesenchymal transition and stemness of large‑cell lung cancer cells and tumorigenesis in xenografts via inhibiting the NF‑κB and p38 MAPK signaling pathways

CLEC12B suppresses lung cancer progression by inducing SHP-1 expression and inactivating the PI3K/AKT signaling pathway

Ezh2 Promotes Malignant Behaviors Via Cell Cycle Dysregulation And Its Mrna Level Associates With Prognosis Of Patient With Non-Small Cell Lung Cancer

EZH2-mediated Epigenetic Suppression of Long Noncoding RNA SPRY4-IT1 Promote S NSCLC Cell Proliferation and Metastasis by Affecting the Epithelial–mesenchymal Transition

EGF-induced nuclear localization of SHCBP1 activates β-catenin signaling and promotes cancer progression

SH3BGRL As a Novel Prognostic Biomarker is Down-Regulated in Acute Myeloid Leukemia

EGR1 Decreases the Malignancy of Human Non-Small Cell Lung Carcinoma by Regulating KRT18 Expression.

TGF-β1/SH2B3 axis regulates anoikis resistance and EMT of lung cancer cells by modulating JAK2/STAT3 and SHP2/Grb2 signaling pathways

SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane

Expression of Sonic Hedgehog (SHH) in human lung cancer and the impact of YangZheng XiaoJi on SHH-mediated biological function of lung cancer cells and tumor growth.

Enhancer of Zeste Homolog 2 is a Novel Prognostic Biomarker in Nonsmall Cell Lung Cancer

The Expression and Significance of the Enhancer of Zeste Homolog 2 in Lung Adenocarcinoma.

CBX2 and EZH2 Cooperatively Promote the Growth and Metastasis of Lung Adenocarcinoma

EP1.03-03 Association Between Molecular Spectrum of EZH2 Variants and Prognosis in Patients with Non-Small-Cell Lung Cancer in Chinese Patients

Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer